Print Friendly, PDF & Email

NCT/Study#

NA /

KO-MEN-001

KO-539 Menin-KMT2A (MLL) inhibitor Phase ½ R/R AML with NPM1 Mutation) A Phase 1/2A First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemi

DISEASE GROUP:
Leukemia
current phase:
Phase I/II
STUDY STATUS:
Active
Location:
Hackensack, NJ
For More information: